The charts of Cytokinetics (CYTK) have caught my attention. Let's take a look at this late-stage bio-pharmaceutical company that is focused on muscle activators and inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining.
More from Investing
These well-known names are displaying noteworthy technical deterioration.
Aggressive trading is not inconsistent with a cautious market approach.
Among the things to watch: How Q3 demand is trending for markets such as smartphones, online advertising, streaming and e-commerce.
There is little for prudent market players to do but to stay with the trend, even if it feels silly to do so.